Ian Lorimer profile picture

Contact Information

Ian Lorimer, PhD

Ottawa Hospital Research Institute
Centre for Cancer Therapeutics
501 Smyth Road
Box 926
Ottawa, ON
K1H 8L6

Ian Lorimer

Senior Scientist, Cancer Therapeutics Program
Ottawa Hospital Research Institute
Associate Professor
University of Ottawa
J. Adrien & Eileen Leger Chair in Cancer Research

Research Interests

The phosphoinositide 3-kinase pathway in cancer:

A very common event in cancer is the aberrant activation of a signalling pathway known as the phosphoinositide 3-kinase pathway. We are studying this pathway with the goal of identifying and evaluating novel targets for cancer therapy. Our recent work has focused on the role of a protein kinase known as atypical protein kinase C. This kinase is best known for its role in cell polarity, but our work has shown that it also has important roles in promoting proliferation, invasion and resistance to chemotherapy in cancer cells.

Currently a major focus of our lab is to characterize the role of the phosphoinositide 3-kinase pathway in tumour-initiating cells that we have isolated from brain tumour patients at the Ottawa Hospital. These tumour-initiating cells represent a clinically relevant model to assess the potential of atypical protein kinase C and other signalling molecules as drug targets. We make use of inducible lentiviral vector technology to modify signalling pathways in these cells and then determine the effects on cancer cell behaviour. In addition we are using tumour-initiating cells from patients to screen for and test novel therapeutic strategies ranging from small molecule inhibitors to oncolytic viruses.

Keywords:  cancer; PI-3kinase; atypical protein kinase C; glioblastoma; experimental therapeutics

Brief Biography

Selected Publications

Jahani-Asl A, Yin H, Soleimani VD, Chang NC, Sincennes M-C, Luchman HA, Puram SV,
Scott AM, Lorimer IAJ, Ligon KL, Weiss S, Rudnicki MA, Bonni A (2016) EGFRvIII Requires OSMR as a Co-Receptor to Drive Glioblastoma Tumorigenesis, Nature Neuroscience, 19:798-806

Restall IJ, Parolin DAE, Daneshmand M, Hanson JEL, Simard MA, Fitzpatrick ME, Kumar R, Lavictoire SJ, Lorimer IAJ (2015) PKCι depletion initiates mitotic slippage-induced senescence in glioblastoma, Cell Cycle, 14: 2938-48

Lorimer IAJ (2015) Atypical PKCι as a target for glioblastoma therapy. Current Cancer Drug Targets 15:136-44

Gont A, Hanson JEL, Lavictoire SJ, Daneshmand M, Nicholas G, Woulfe J, Kassam A, Da Silva VF, Lorimer IAJ (2014) Inhibition of glioblastoma malignancy by Lgl1, Oncotarget, 5, 11541-51

Karapetis C , Jonker D, Daneshmand M, Hanson J, Marginean C, O'Callaghan C, Tebbutt N, Price T, Tu D, Simes J, Zalcberg J, Lorimer IAJ (2014) BRAF, PIK3CA and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer: results from NCIC CTG / AGITG CO.17, Clinical Cancer Research, 20, 744-53  

Liwak U, Jordan LE, Von-Holt SD, Singh P, Hanson JE, Lorimer IA, Roncaroli F, Holcik M (2013) Loss of PDCD4 contributes to enhanced chemoresistance in glioblastoma multiforme through de-repression of Bcl-xL translation. Oncotarget, 4, 1365-72

Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, Edelman MJ, Lilenbaum R, Choy H, Khuri F, Pisters K, Gandara D, Kernstine K, Butts C, Noble J, Hensing TA, Rowland K, Schiller J, Ding K, Shepherd FA (2013) Gefitinib versus Placebo in Completely Resected Non-Small Cell Lung Cancer, Results of the NCIC CTG BR19 Study. J. Clin. Oncology, 31, 3320-6

Gont A, Hanson JEL, Lavictoire SJ, Parolin DAE, Daneshmand M, Restall IJ, Soucie M, Nicholas G, Woulfe J, Kassam A, Da Silva VF and Lorimer IAJ (2013) PTEN loss represses glioblastoma tumor initiating cell differentiation via inactivation of Lgl1. Oncotarget, 4, 1266-1279

Daneshmand D, Hanson JEL, Nabavi M, Hilton JF, Vandermeer L, Kanji F, Dent SF, Clemons M, Lorimer IAJ (2012) Detection of PIK3CA mutations in breast cancer bone metastases, ISRN Oncology, 492578. Epub 2012 Aug 30